China-focused CRO BioDuro has merged with manufacturing company Formex in the U.S. as part of an apparent reorganization under owner Bridgewest Group with all three companies located in San Diego.
A U.S. court has barred Dr Reddy's Laboratories from selling its generic of AstraZeneca's heartburn drug Nexium after AstraZeneca objected to the Indian drugmaker's use of the color purple for the pills, according to reports.
Dr Reddy's Laboratories has again come under the spotlight of the U.S. Food and Drug Administration which has ordered a third-party audit covering the entire manufacturing network of the company, according to a report by Livemint.
Mumbai-based Sun Pharmaceutical Industries saw net profit slump nearly a third in its financial second quarter as costs related to its purchase of troubled Ranbaxy Laboratories continue to hound operations.
In this day of instant gratification, instant feedback via social media and fast food and fast fashion, General Electric wants to add fast prefabricated drug manufacturing plants to the list.
India's Dr Reddy's Laboratories is looking to increase sales of biosimilars in emerging markets and plans to launch products in Russia as well as licensing deals in Southeast Asia, its chief operating officer told an earnings call, according to a Reuters report.
Swiss-based Novartis will close a manufacturing plant in India, CEO Joe Jimenez said on the Oct. 27 third quarter earnings call, noting that the company has moved on remediation plans following inspections, but still received a U.S. FDA warning letter.
A manufacturing pact in China's Chongqing will see U.S.-based Athenex build two drug manufacturing plants at Banan that will receive local funding for land and construction, the company formerly known as Kinex said in a press release.
A move in the past week by Vietnam to say it wants to sell major stakes in state-owned companies might be a dealmaking cue for Abbott Laboratories, which noted a sharp slowdown in nutrition sales in Vietnam in the second quarter.
Small and medium-sized Indian drugmakers are decrying a move by the government to impose new bar-code requirements and say the action shows the government is taking sides with big multinational players to elbow out smaller competition. The larger companies are saying the move is necessary to protect the country's reputation.